Breast implant stocks surge

Allergan, Mentor stock prices shoot up following FDA approval of silicone breast implants.

By Aaron Smith, staff writer

NEW YORK ( -- Stock prices for breast implant makers surged on Monday, following the FDA's decision on Friday to approve silicone implants, ending a 14-year ban for most women.

In the first full day of trading since the ban was lifted, the stock price for Allergan (up $8.82 to $121.32, Charts) of Irvine, Calif., was up 8 percent in the late afternoon, while the price for Mentor Corp. (up $5.20 to $52.78, Charts) of Santa Barbara was up 10 percent.

The Food and Drug Administration approved the use of silicone on Friday after the markets closed, ending a ban that had been in place since 1992. In that time, silicone implants in the U.S. were available only for women in need of postmastectomy reconstructive surgery.

Allergan and Mentor sell silicone implants in Europe and South America and saline implants in the United States. With the FDA's reapproval of silicone for the general population, the $350 million U.S. market for breast implants is expected to double.

Proponents of silicone believe it holds a better shape than saline, though its opponents say that it poses health risks to women.

Silicone implants are back Top of page

Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?